Actively Recruiting

Phase Not Applicable
Age: 2Years +
All Genders
Healthy Volunteers
NCT07415837

Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies

Led by University Hospital, Clermont-Ferrand · Updated on 2026-02-25

104

Participants Needed

1

Research Sites

159 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Clermont-Ferrand

Lead Sponsor

I

iGreD, Université Clermont Auvergne

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases. MicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease. The main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities: 1. Patients with Duchenne or Becker muscular dystrophy (DMD/DMB). 2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease). 3. Patients with congenital myopathies. 4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.

CONDITIONS

Official Title

Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies

Who Can Participate

Age: 2Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be older than 2 years of age
  • Participants or their legal guardians must provide free and informed consent
  • For children under 6 years old, consent is oral; for those over 6, consent is written
  • Participants must be affiliated with the French social security system
  • Participants must have a diagnosed neuromuscular disease: Myotonic Dystrophy Type 1, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, congenital myopathies, or be healthy volunteers
Not Eligible

You will not qualify if you...

  • Refusal to participate by the participant or their legal guardian
  • Intense or unusual physical effort within 10 days before blood draw
  • Current use of treatments affecting systemic, muscular, or cardiac function that might interfere with results
  • Participants under legal protection such as tutelage, curatorship, deprivation of liberty, or judicial protection
  • Women who are pregnant or breastfeeding
  • Presence of another disease that could interfere with biological findings according to the clinician

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHU de Clermont-Ferrand

Clermont-Ferrand, France

Actively Recruiting

Loading map...

Research Team

L

Lise Laclautre, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here